Semaglutide vs Ozempic: Are They the Same Drug?

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist — a class of medication that mimics glucagon-like peptide-1, a hormone naturally produced in the gut after eating. GLP-1 signals the pancreas to release insulin, slows gastric emptying (so food stays in the stomach longer), and most importantly for weight management, sends satiety signals to the brain that reduce appetite.

Semaglutide was developed by Novo Nordisk and received its first FDA approval in 2017 for type 2 diabetes management. In 2021, it received a separate FDA approval for chronic weight management under the brand name Wegovy — at a higher weekly dose. The STEP trials for Wegovy showed an average body weight reduction of 14.9% over 68 weeks, making it one of the most effective pharmaceutical weight loss treatments ever approved.

The Three Semaglutide Brands: What Is Different

Brand list prices are approximate and vary by insurance coverage. Compounded pricing varies by provider and pharmacy.

Why Does Novo Nordisk Sell the Same Drug Under Three Names?

This is a common pharmaceutical strategy. FDA drug approvals are indication-specific — each new indication (diabetes vs. obesity vs. oral dosing) requires separate clinical trials and approval. A company that runs those trials receives a distinct product approval with its own patent protection, pricing, and reimbursement negotiations.

The practical result: the exact same molecule costs different amounts depending on what you say you are using it for — and whether your insurance covers that specific indication. Many insurance plans cover Ozempic for diabetes but not Wegovy for weight loss, even though they are the same drug at different doses.

What Is Compounded Semaglutide?

Compounded medications are prepared by licensed compounding pharmacies using pharmaceutical-grade active pharmaceutical ingredients. Compounding is governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide is not an FDA-approved drug — the FDA does not review compounded preparations for safety, effectiveness, or quality before they are dispensed, and a compounded product is not a generic.

What changed in 2025 — and what the rules are now

For roughly two years, the legal basis for most compounded GLP-1s was the drug shortage list: while a drug is in shortage, pharmacies may compound copies of it. That window has closed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Enforcement discretion for shortage-based compounding then ended on a published schedule — March 2025 for tirzepatide, and April 22, 2025 (503A pharmacies) and May 22, 2025 (503B outsourcing facilities) for semaglutide. Industry groups sued to block both determinations; the courts declined, and the deadlines held.

Compounded semaglutide did not become illegal — the basis for it changed. Section 503A separately permits a pharmacy to compound a preparation for an individual patient against a valid prescription, regardless of shortage status, provided it is not essentially a copy of a commercially available FDA-approved drug without a documented clinical reason for that specific patient. That is a narrower, prescription-by-prescription basis, and it is the reason a legitimate program now runs through a real provider evaluation rather than a checkout button.

The price gap is still the reason patients ask about it. Brand-name Wegovy runs roughly $1,300 per month at list without insurance, and manufacturer direct-to-patient programs have brought cash prices to roughly $349 (Wegovy) and $299–$449 (Zepbound) depending on dose. Affinity Direct’s compounded semaglutide starts at $96.05/mo effective on a 3-month auto-refill plan, or $159 for a one-time one-month supply, with medication, injection supplies, shipping and provider review included. Competitor and manufacturer prices above were checked in August 2026 and change often — verify them at the source before relying on them.

Important caveat: compounding rules continue to move, and a provider decides what is appropriate for you. Prescription weight-loss medication is only available if a licensed provider determines it is appropriate after reviewing your health intake.

How Effective Is Semaglutide for Weight Loss?

The STEP 1 trial — 68 weeks of semaglutide 2.4mg weekly — produced a mean weight reduction of 14.9% of body weight. For a 220-pound person, that is approximately 33 pounds. The placebo group lost 2.4%. These are the largest sustained weight loss results ever observed in a pharmaceutical trial at the time.

Results require consistent use and are not permanent. Weight typically returns when medication is stopped, because GLP-1 agonists are treating the underlying hormone signaling, not permanently changing it. This positions semaglutide as a long-term maintenance therapy, not a short course.

Common Questions

This article is written and reviewed by the Affinity Direct clinical team for informational purposes. It does not constitute medical advice. All prescriptions require a provider evaluation. Compounded semaglutide is prepared by licensed U.S. compounding pharmacies and is not FDA-approved; the FDA does not review compounded medications for safety, effectiveness, or quality before they are dispensed. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Individual results vary and no amount of weight loss is guaranteed. Compounding rules are subject to change. Last reviewed: August 2026.